IPO Stream — Biotech For The Week — August 3–7, 2026
IPO STREAM
FIRST IN WINS
BIOTECH FOR THE WEEK
IT'S THE BIG TREND
Week of August 3 – 7, 2026 · ipostream.com
4 IPOs This Week · Immune Disease · Cardiovascular · Metabolic · Regional Bank · Published August 3, 2026
Good morning all and welcome to this week's IPO Stream write-up. It's a biotech-heavy stretch with four traditional IPOs on the calendar. Let's get into the meat and potatoes right away so you can be confident and informed.
Pricing schedule: Attovia (ATTO) prices Wednesday · Braveheart Bio (BRVE), Vogenx (VOGX), and River City Bank (RCBC) all price Thursday
THIS WEEK AT A GLANCE
| Company |
Ticker |
Raise |
Price Range |
Pricing Day |
Lead Banks |
| Attovia Therapeutics |
ATTO |
$200M |
$15–$17 |
Wednesday |
MS, Leerink, Citi, RBC |
| Braveheart Bio |
BRVE |
$300M |
$15–$17 |
Thursday |
Goldman, Jefferies, TD Cowen |
| Vogenx |
VOGX |
$75M |
$11–$13 |
Thursday |
JonesTrading |
| River City Bank |
RCBC |
$136M |
$48–$51 |
Thursday |
Raymond James, KBW |
FULL BREAKDOWN
Nasdaq · Pricing Wednesday · ATTOBODY Nanobody Platform
|
Attovia Therapeutics
ATTO
|
Immune Disease Biotech
|
|
Raise / Price
$200M @ $15–$17
|
Lead Underwriters
Morgan Stanley, Leerink Partners
Citi, RBC Capital, LifeSci Capital
|
Shares
12.5M shares
|
Uses its proprietary ATTOBODY nanobody platform to create next-generation antibody therapies for immune-mediated diseases. Morgan Stanley and Leerink Partners leading alongside Citi, RBC, and LifeSci Capital for a $200M Nasdaq raise.
Biotech IPOs are back when the science is differentiated and the market is hungry for innovation. Attovia could ride any healthcare rotation if early data stays strong.
Nasdaq · Pricing Thursday · Phase 3-Ready · Goldman Sachs Lead
|
Braveheart Bio
BRVE
|
Cardiovascular Biotech
|
|
Raise / Price
$300M @ $15–$17
|
Lead Underwriters
Goldman Sachs, Jefferies
TD Cowen, Stifel, Cantor
|
Lead Program
Oral small molecules
Hypertrophic cardiomyopathy
|
Phase 3-ready cardiovascular biotech developing oral small molecules for hypertrophic cardiomyopathy and other serious heart conditions. Goldman Sachs leading with Jefferies, TD Cowen, Stifel, and Cantor on the $300M Nasdaq raise.
A relatively de-risked late-stage story in a large unmet-need area. Cardio has been a quiet but steady IPO sector — Goldman's involvement is a meaningful signal of institutional demand.
Nasdaq · Pricing Thursday · Niche Metabolic Conditions
|
Vogenx
VOGX
|
Metabolic Biotech
|
|
Raise / Price
$75M @ $11–$13
|
Underwriter
JonesTrading
|
Target Conditions
Post-bariatric hypoglycemia
Gastroparesis
|
Develops medicines for hormone-related and metabolic conditions — specifically low blood sugar after bariatric surgery and gastroparesis. A smaller, higher-risk metabolic play with 6.3M shares at $11–$13. Could appeal to specialists looking for niche biotech exposure in underserved indications.
Nasdaq · Pricing Thursday · California Commercial Bank
|
River City Bank
RCBC
|
Regional Bank
|
|
Raise / Price
$136M @ $48–$51
|
Underwriters
Raymond James
Keefe Bruyette & Woods
|
Shares
2.8M shares
|
California commercial bank raising $136M at $48–$51 — the only non-biotech name this week. Raymond James and KBW (the specialist bank underwriter) leading. A rare bank IPO in a fragmented regional market. Interesting as a steady financial play if interest rates stabilize and M&A in banking heats up.
Keep in mind — the market fluctuates often and more IPOs can be added at a moment's notice. We'll let you know if anything changes.
"That's what we have going on this week. Have a great week."
Tim
IPO Stream
